Main objective: To characterize the safety and tolerability of escalating doses of the rBCG-N-hRSV vaccine, including doses of 5x10^3, 5x10^4 and 5x10^5 CFU (1%, 10% and 100% of the total dose) in healthy adult males of 18 to 50 years of age.